A Closer Look at 11 Analyst Recommendations For Crinetics Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past three months, 11 analysts have shared their evaluations of Crinetics Pharmaceuticals (NASDAQ:CRNX), with a mix of bullish and somewhat bullish ratings. Analysts have set a 12-month average price target of $68.64, reflecting a 7.86% increase from the previous average. Key analysts have adjusted their ratings and price targets, indicating varied perspectives on the company's future performance. Despite challenges in revenue growth and profitability, the company maintains a balanced debt approach.
August 09, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Crinetics Pharmaceuticals (NASDAQ:CRNX) received mixed evaluations from 11 analysts, with an average 12-month price target of $68.64, reflecting a 7.86% increase. Despite revenue and profitability challenges, the company maintains a balanced debt approach.
The mixed analyst ratings and the upward revision of the average price target suggest a positive short-term outlook for CRNX. However, the company's revenue and profitability challenges may temper this optimism. The balanced debt approach is a positive factor.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100